Table 2 Pathological response

From: The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction

 

Full analysis set (n = 36)

Surgery set (n = 33)

Becker’s TRG

1a

12 (33.3)

12 (36.4)

1b

4 (11.1)

4 (12.1)

2

8 (22.2)

8 (24.2)

3

9 (25.0)

9 (27.3)

UTA

3 (8.3)

0

pCR rate

12 (33.3)

12 (36.4)

95% CI

18.6–51.0

20.4–54.9

tpCR rate

12 (33.3)

12 (36.4)

95% CI

18.6–51.0

20.4–54.9

MPR rate

16 (44.4)

16 (48.5)

95% CI

27.9–61.9

30.8–66.5

  1. Data were n (%) unless otherwise stated.
  2. TRG tumor regression grade, pCR pathological complete response, UTA unable to access, tpCR total pathological complete response, MPR major pathological response, CI confidence interval.
Back to article page